drugset / Trial / NCT02674776

Efficacy and Safety of HuZhen Capsule for Treatment of Patients With Acute Gout

NCT02674776 ↗

Phase 3 Unknown 480 enrolled Quan Jiang
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a multi-center, double-blind, randomized, parallel controlled trial. Patients with acute gout will be enrolled and randomly allocated into 2 groups: HuZhen capsule treatment group and Placebo control group. Randomization codes were established by the biostatistician. Observe will be followed for 3 days (72 hours) after the onset. Change of VAS score from baseline, proportion of improvement with damp-heat retention, change in C-reactive protein (CRP) and erythrocyte sedimentation rate ( ESR) from baseline, change in white blood cell count in whole blood cell analysis from baseline, and the number of adverse events will be monitored and compared between each groups.

Timeline

Start
2015-09
Primary completion
2016-12
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Subject HuZhen Capsule Unknown 1.6 g —

Indications